Related Experiment Videos
Synagis: an anti-RSV monoclonal antibody
1University of North Carolina Hospitals, Chapel Hill, NC, USA.
Insights
Palivizumab significantly reduced respiratory syncytial virus (RSV) hospitalizations by 55% in high-risk infants. This monoclonal antibody also decreased illness severity, though its cost-effectiveness requires further evaluation.
Area of Science:
- Pediatric Infectious Diseases
- Immunology
- Respiratory Medicine
Background:
- Respiratory Syncytial Virus (RSV) poses a significant threat to high-risk pediatric populations.
- Serious lower respiratory tract disease caused by RSV necessitates preventative strategies.
Purpose of the Study:
- To evaluate the efficacy of palivizumab (Synagis) in preventing RSV-related hospitalizations in high-risk infants.
- To assess the impact of palivizumab on the severity of RSV illness in pediatric patients.
Main Methods:
- A large, single clinical trial (IMpact) assessed palivizumab's effectiveness.
- Study population included infants born prematurely and those with Bronchopulmonary Dysplasia (BPD).
Main Results:
- Palivizumab reduced RSV hospital admissions by 55% in eligible children.
- A decrease in total hospitalization days and intensive care unit admissions was observed.
- The cost of palivizumab prophylaxis ranges from $3,500-$10,700 per infant per season.
Conclusions:
- Palivizumab demonstrates significant efficacy in reducing RSV hospitalizations and illness severity in high-risk infants.
- The high cost of palivizumab necessitates formal cost-effectiveness evaluations.
- American Academy of Pediatrics (AAP) guidelines assist in identifying optimal candidates for RSV prophylaxis.
Abstract:
Palivizumab is a new anti-RSV monoclonal antibody product indicated for the prevention of serious lower respiratory tract disease caused by RSV in pediatric patients at high risk of developing RSV disease ("Synagis," 1998). Palivizumab was evaluated in a single, large clinical trial (IMpact) (Connor et al., 1998). In this trial, RSV hospital admissions were reduced by 55% in children 24 months of age with BPD or in infants born prematurely (35 weeks gestation). Additionally, the severity of illness was also reduced as evidenced by a decrease in total days of RSV hospitalization and decreased incidence of RSV intensive care unit admissions. Palivizumab is expensive--with an estimated cost for a season ranging from $3,500-$10,700 per infant, depending on the child's weight and length of RSV season in the area where the child resides. Although palivizumab prophylaxis has been shown to reduce hospital admissions, the cost effectiveness of using this product needs to be formally evaluated. The AAP has provided guidance to determine the best candidates for RSV prophylaxis.